Los Angeles Capital Management’s Tango Therapeutics TNGX Stock Holding History

Los Angeles Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$84.6K	Sell	2,706 -60,514	-96%	-$1.5M	﹤0.01%	1397
2026 Q1	$1.32M	Sell	63,220 -1,023	-2%	-$14.2K	0.01%	599
2025 Q4	$512K	Buy	64,243 +47,058	+274%	+$405K	﹤0.01%	878
2025 Q3	$144K	Buy	17,185 +6,895	+67%	+$46.7K	﹤0.01%	1306
2025 Q2	$52.7K	Sell	10,290 -118,820	-92%	-$294K	﹤0.01%	1301
2025 Q1	$177K	Buy	129,110 +58,658	+83%	+$144K	﹤0.01%	1038
2024 Q4	$218K	Buy	+70,452	New	+$327K	﹤0.01%	1034

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Los Angeles Capital Management's TNGX Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Tango Therapeutics (TNGX) stake by 96% in Q2 2026, selling an estimated $1.5M and leaving 2,706 shares worth $84.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

Los Angeles Capital Management first reported a position in TNGX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.32M in Q1 2026. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

Los Angeles Capital Management held 2,706 shares of Tango Therapeutics worth $84.6K as of Q2 2026.
Los Angeles Capital Management sold 60,514 Tango Therapeutics shares in Q2 2026, an estimated $1.5M.
Tango Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1397 holding.
Los Angeles Capital Management first reported a position in Tango Therapeutics in Q4 2024 and has held it in 7 quarters since.
Los Angeles Capital Management's Tango Therapeutics position peaked at $1.32M in Q1 2026.
248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.